This announcement contains inside
information as stipulated under the UK version of the
Market Abuse Regulation No 596/2014 which is part of English law by
virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
20 February
2025
EDX Medical Group
plc
AQSE: EDX
("EDX Medical" or the "Group"
or "Company")
DIRECTOR
DEALING
CAMBRIDGE, UK: EDX Medical
Group, plc ("EDX Medical", the "Company" or the "Group"), which
develops innovative digital diagnostic products and services for
the personalised treatment for cancer, cardiovascular and
infectious diseases, today announces that Professor Sir Christopher
Evans OBE, founder, director and Chief Scientific Officer of the
Company, purchased 20,000 ordinary shares in the Company on
February 19, 2025 at an average price per share of 13.5
pence.
Following these
purchases, Professor Evans owns 130,590,000 ordinary
shares, representing 37.3% of the issued share
capital.
The directors of the Company accept
responsibility for the contents of this announcement.
ENDS
Contacts
|
EDX
Medical Group Plc
|
|
|
Dr Mike Hudson (Chief
Executive Officer)
|
+44 (0)7812 345 301
|
|
|
|
|
Oberon Capital
|
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20 3179 5300
|
|
|
|
|
IFC
Advisory (Investor Relations)
|
|
|
Tim Metcalfe
|
+44 (0)20 3934 6630
|
|
Graham Herring
|
|
|
|
|
|
Media House International
|
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
Notes for
Editors:
About EDX Medical Group plc
The EDX Medical
Group plc is listed on the Apex Segment of the AQSE
Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights
into pragmatic solutions combining advanced biological and digital
technologies, EDX Medical seeks to cost effectively improve the
detection and characterisation of disease in order to personalise
treatment in a timely fashion. Early disease detection and
biologically-based personal treatment optimisation is considered to
be the most impactful way of reducing deaths and lowering the cost
of healthcare globally.
EDX Medical Group provides
doctors, hospitals and insurers/payers with access to a portfolio
of the best clinical diagnostics products and services. The Company
operates its own facilities in Cambridge and Oxford,
UK, and has a number of significant strategic partnerships
including; a product technology collaboration with Thermo
Fisher EMEA Ltd, a logistics partnership with Fedex and a
distribution agreement with Caris Life Sciences inc, each
world leaders in their respective fields.
www.edxmedical.com
